Kazia Therapeutics Limited (KZIA)
| Market Cap | 90.72M +550.6% |
| Revenue (ttm) | 1.27M -24.2% |
| Net Income | -15.21M |
| EPS | -6.82 |
| Shares Out | 13.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 352,750 |
| Open | 6.88 |
| Previous Close | 6.95 |
| Day's Range | 6.26 - 7.00 |
| 52-Week Range | 4.86 - 17.40 |
| Beta | 2.36 |
| Analysts | Strong Buy |
| Price Target | 28.76 (+334.44%) |
| Est. Earnings | Nov 27, 2026 |
About KZIA
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met... [Read more]
Financial Performance
In fiscal year 2025, Kazia Therapeutics's revenue was 1.83 million, a decrease of -26.28% compared to the previous year's 2.48 million. Losses were -20.70 million, -22.69% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for KZIA stock is "Strong Buy." The 12-month stock price target is $28.76, which is an increase of 334.44% from the latest price.
News
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
SYDNEY, Nov. 12, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram c...
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology...
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov. 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a...
Kazia Therapeutics initiated with a Buy at Needham
Needham initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $27 price target. The recent approval of Celcuity’s (CELC) IV administered Revtorpyk in 2nd line WT PI3K HR+/HER2-…
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
SYDNEY, Oct. 29, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-...
Kazia Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Paul Jeng initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $35 price target Kazia’s lead asset paxalisib is in development for advanced breast cancer and…
Leerink bullish on Kazia Therapeutics, initiates with an Outperform
As previously reported, Leerink initiated coverage of Kazia Therapeutics (KZIA) with an Outperform rating and $30 price target The firm is developing paxalisib, a brain-penetrant, oral PI3K/mTOR inhib...
Kazia Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Kazia Therapeutics (KZIA) with an Outperform rating and $30 price target
Kazia Therapeutics management to meet with BTIG
Biotechnology Analyst Yazdi holds a group dinner meeting with management in New York on October 28 at 5:30 pm hosted by BTIG.
Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial
Kazia Therapeutics (KZIA) announced that Sovargen, a biotechnology company specializing in central nervous system diseases that has exclusively licensed paxalisib from Kazia for the development and co...
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncolo...
Kazia Therapeutics announces first patient dosed in PNOC035 study
Kazia Therapeutics (KZIA) announced that the first patient has been dosed in Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib in combination with gemcitabine for patients ages…
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist SYDNEY, Sept. 9, 2026 /PRNewswir...
Kazia Therapeutics price target raised to $40 from $34 at BTIG
BTIG raised the firm’s price target on Kazia Therapeutics (KZIA) to $40 from $34 and keeps a Buy rating on the shares after the company announced new preclinical and translational…
Kazia Therapeutics announces new preclinical, translational data on paxalisib
Kazia Therapeutics (KZIA) announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% in microsatellit...
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerate...
Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics (KZIA) announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6...
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Ev...
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focu...
Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50
Leerink and Guggenheim acted as joint book running managers for the offering.
Kazia Therapeutics announces pricing of $120M public offering
Kazia Therapeutics (KZIA) announced the pricing of its previously announced tranched registered public offering of (i) 2,580,000 American Depositary Shares, each representing five hundred ordinary sha...
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram ca...
Kazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment
Kazia Therapeutics (KZIA) announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer, or TNBC. Fi...
Kazia Therapeutics announces offering of ADS, warrants
Kazia Therapeutics (KZIA) announced that it has commenced a tranched registered public offering of (i) American Depositary Shares, each representing five hundred ordinary shares of the company, no par...
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram ca...